Home | Mini Mixiii Miami

January 8th 2026

The LAB | Wynwood Miami

MIXiii is Coming to Miami!

Mini MIXiii is IATI's satellite event of the MIXiii Health-Tech.IL Conference, serving as an annual gathering for the Life Science and Health Tech industries in Israel.

IATI is thrilled to announce that, for the second time, Mini MIXiii will be held in Miami on January 8th 2026 at The LAB Miami.

This Symposium will showcase leading Israeli Health-Tech startups, offering them the opportunity to connect with key players in the local Miami health tech ecosystem. Attendees can look forward to a focused and dynamic agenda featuring professional networking opportunities, pitch sessions and one-on-one meetings.

Mini MIXiii is an excellent platform for the global Health-Tech industry to exchange knowledge, network, and drive the industry forward into the future.

About the event

Highlights from 2025:

Showcasing Israeli Companies Leaders 2026

Yaky Yanay

CEO &President

Pluri

Tehila Ben Moshe

CEO & Founder

Biond Biologics

Ilan Uchitel

CEO & Co Founder

CAPS Medical

Gili Hart

CEO

SpliSense

Eran Ophir

President & CEO

Compugen

Shahar Karny

Co-founder and CEO

PhenoTA

Ofer Gonen

CEO

MediWound

Fabian Tenenbaum

CEO

Nectin

Boaz Almog

CEO

Agile MRI

Eyal Shamir

CEO

IceCure

Yaacov Michlin

Chairman

OCUVIA

Startups

Participating Israeli Health-Tech & Life Science Companies

Pluri

Pluri™ is pioneering a biotech revolution with its patented 3D cell-expansion technology, delivering accurate, scalable, and cost-efficient cell production. Its platform powers innovations in regenerative medicine, foodtech, and agtech, and supports partners through CDMO services. By advancing state-of-the-art cell engineering, Pluri helps address global challenges in health, sustainability, food security, and animal welfare.

SpliSense

SpliSense is a clinical-stage biotech developing inhaled RNA-based antisense oligonucleotide (ASO) therapies for severe pulmonary diseases, including cystic fibrosis, COPD, asthma, non-CF bronchiectasis, and IPF. With positive Phase 2 efficacy data in CF and two additional programs entering the clinic by 2026, SpliSense’s platform offers a novel, mutation-independent approach to treating respiratory diseases.

MediWound

MediWound is a global biotechnology company developing and commercializing enzymatic therapies for non-surgical tissue repair. Its FDA-approved biologic, NexoBrid®, removes eschar in burn injuries and is marketed in major regions worldwide. The company’s late-stage candidate, EscharEx®, targets chronic wounds, showing superior clinical outcomes and addressing a significant global market opportunity.

IceCure

IceCure Medical (Nasdaq: ICCM) develops advanced liquid nitrogen-based cryoablation systems for the minimally invasive destruction of tumors by freezing them. Its ProSense System is the first and only FDA-cleared medical device for the local treatment of low-risk breast cancers for women 70 & up when combined with endocrine therapy, giving patients a safe and effective outpatient option to surgery. ProSense is currently sold in the US, Europe, Brazil, and Asia.

Biond Biologics

Biond Biologics is a clinical-stage biotech, advancing a innovative pipeline of first-in-class immunotherapies. our key assets: - BND-67 – A first in-class anti CD28 shedding antibody that restores T cell activation driving anti-tumor responses. BND-67 is IND ready, Phase 1 initiation in H1 2026. - BND-22 (SAR444881) – A phase 2A first-in-class ILT2 immune checkpoint inhibitor. - BND-35 – A highly differentiated anti-ILT3 antibody in Phase 1 dose escalation. It blocks all known ILT3 ligands and enhances Fc-effector activity.

Compugen

Compugen Ltd. (Nasdaq/TASE: CGEN) a clinical-stage cancer immunotherapy company pioneering AI/ML-powered drug target discovery via its Unigen™ platform. Its Fc-reduced antibody pipeline includes clinical stage fully owned COM902 (anti-TIGIT), COM701 (anti-PVRIG), and partnered GS-0321 (anti-IL-18BP, licensed to Gilead) as well as Phase 3 rilvegostomig- AstraZeneca’s PD-1/TIGIT bispecific, TIGIT component derived from COM902. Strategic partnerships and differentiated assets position Compugen for long-term growth.

NectinTx

Nectin Therapeutics is a biotechnology company pioneering next-generation immuno-oncology and antibody-drug-conjugate therapies to transform cancer treatment. Founded in 2017 from research at the Hebrew University of Jerusalem and the University of Rijeka, Nectin’s innovative mAbs and ADCs target key immune escape mechanisms. Its lead anti-PVR program is in phase 1b for advanced solid tumors with MD Anderson and Merck.

Ocuvia

Ocuvia (subsidiary of Biolight) is an ocular-drug delivery company solving one of eye medicine’s biggest challenges: getting therapeutics safely and effectively into the eye. Using two clinically validated platforms—high-dose nano-droplet eye drops and long-acting subconjunctival implants. The droplets (Ocudrip) demonstrated efficacy similar to known injections for AMD and proved safety in humans. The implant (Ocugrid) demonstrated efficacy and safety in PI/IIa in the US.

CAPS

CAPS Medical, a clinical-stage MedTech company pioneering a disruptive non-thermal plasma therapy the first endoscopic, selective, minimally invasive treatment of solid tumors, sparing surrounding healthy tissue.Our proprietary PlasmaSure™ platform has received a Breakthrough Device designation from the FDA. It delivers the treatment endoscopically, enabling precise tumor eradication — without resection, hospitalization, or anaesthesia, representing a step-change in oncology care: tissue-preserving, safer, and fully compatible with robotic and endoscopic systems.

Agile MRI

Agile MRI is disrupting musculoskeletal care with a compact, affordable MRI system that delivers rapid, high-value imaging wherever traditional MRI is impractical or unavailable. By giving orthopedic clinics, sports teams, and frontline providers immediate diagnostic insight, Agile MRI enables faster decisions and new revenue opportunities, aiming to make MRI as routine and accessible as X-ray for clinicians nationwide.

PhenoTA

PhenoTA automates complex manual work in routine lab testing and brings Raman spectroscopy into standard CBCs. Its agent provides real-time insight for faster decisions. The first system is live in Israel, with US pilots planned with leading strategics. PhenoTA raised 6 million dollars and, after a successful FDA presubmission, is preparing its initial 510k study.

MIXiii Health-Tech.IL 2025 Jerusalem- Highlights

Powered by:

Suppurted by:

CLICK HERE TO BOOK

About_IATI

Israel Advanced Technology Industries Association (IATI)

Fostering the Resilience, Global Competitiveness and the Business Continuity of Israel’s Advanced Technology Industries.

A nonprofit Association of Israel’s advanced tech industry players, IATI is on a mission to foster business certainty and stability for advancing Israel’s high-tech and health-tech industries. This, in turn, furthers national resilience and inclusive economic growth and strengthens Israel’s position as a global innovation leader.

Our members include Israeli tech industry players across all segments – Venture Capital and investment funds, growth and established Israeli companies, R&D centers of Multinational Companies, startups, tech transfer organizations, academic institutions, incubators, innovation centers, hospitals, economic development offices, private investors and service providers.

We connect our members with business opportunities and international stakeholders, building impactful bridges with the global community.

For more information and becoming an IATI Member, please click here

January 8th 2026

The LAB | Wynwood Miami

MIXiii is Coming to Miami!

Highlights from 2025:

Showcasing Israeli Companies Leaders 2026

Participating Israeli Health-Tech & Life Science Companies

MediWound

MIXiii Health-Tech.IL 2025 Jerusalem- Highlights

Powered by:

Sponsored by:

Suppurted by:

Israel Advanced Technology Industries Association (IATI)

Contact Us

Our Address

Call Us